22 Jun 2017 --- BioGaia has established a subsidiary, BioGaia Pharma AB, for the development of drugs identified in the research and development conducted in the company's normal operations. Since the foundation of BioGaia the company has focused its development efforts on the regulatory categories dietary supplements and food for special medical purposes. For certain target segments, the company says these categories are limiting and in some cases it lacks distribution channels for pipeline products. For this reason, the board has decided to also develop probiotic drugs through BioGaia Pharma.
